Cleveland Biolabs Inc.
| Article | Date | Source |
|---|
| Researchers from Roswell Park, Cleveland Biolabs Publish Curaxins... | -- | PRWeb - Biotechnology |
| Cleveland BioLabs to Present at 14th Annual BIO CEO and Investor Conference | February 06, 2012 | Marketwire - Pharma and Biotech |
| Cleveland Biolabs Inc. Reorganizes Management, CEO to Step Down | January 24, 2012 | BioSpace |
| Cleveland BioLabs revamps top execs | January 24, 2012 | Health News - BizJournals.com |
| Cleveland BioLabs Announces Management Reorganization | January 24, 2012 | Marketwire - Pharma and Biotech |
| Cleveland BioLabs Publishes Manuscript on New Radiation Countermeasure CBLB613 | January 17, 2012 | Marketwire - Pharma and Biotech |
| Cleveland BioLabs to Present at Noble Financial Eighth Annual Equity Conference | January 11, 2012 | Marketwire - Pharma and Biotech |
| Cleveland BioLabs to Present at 4th Annual LD MICRO Growth Conference | December 01, 2011 | Marketwire - Pharma and Biotech |
| Cleveland Biolabs Inc. to Host Quarterly Update Call on November 10 | November 01, 2011 | BioSpace - Breaking News |
| Cleveland BioLabs to Host Quarterly Update Call on November 10 | November 01, 2011 | Marketwire - Pharma and Biotech |
| International Journal of Radiation Oncology, Biology and Physics Publishes Cleveland BioLabs Study of CBLB502 Protection From Radiation Dermatitis and Oral Mucositis in Head and Neck Cancer Model | October 24, 2011 | Marketwire - Pharma and Biotech |
| Cleveland Biolabs Inc. Announces Opening of New IND for CBLB502 in Cancer Patients | October 19, 2011 | BioSpace - Breaking News |
| Cleveland BioLabs Announces Opening of New IND for CBLB502 in Cancer Patients | October 19, 2011 | Marketwire - Pharma and Biotech |
| <b><i>Journal of Immunology</i></b> Publishes Study of Cleveland Biolabs Inc.' Drug CBLB502 in Acute Renal Ischemic Failure | October 03, 2011 | BioSpace - Breaking News |
| Cleveland BioLabs Enters Into a Joint Venture with Rusnano | September 30, 2011 | Burrill Report |
| Cleveland Biolabs Inc. and Enter into Agreement to Form New Joint Venture for Up to $35 Million Develop Innovative Compounds for Cancer and Infectious Disease | September 26, 2011 | BioSpace |
| Cleveland BioLabs and RUSNANO Enter Into Agreement to Form New Joint Venture to Develop Innovative Compounds for Cancer and Infectious Disease | September 26, 2011 | Marketwire - Pharma and Biotech |
| Cleveland BioLabs awarded $5M grant | September 23, 2011 | Health News - BizJournals.com |
| Cleveland BioLabs Subsidiary Incuron Receives $5 Million Grant From Russian Federation Government Initiative | September 19, 2011 | Marketwire - Pharma and Biotech |
| Cleveland BioLabs to Present at Rodman & Renshaw 13th Annual Healthcare Conference | September 06, 2011 | Marketwire - Pharma and Biotech |
| <b><i>Science Translational Medicine</i></b> Publishes Breakthrough Finding From Cleveland Biolabs Inc. and <b>Incuron</b> on Identification of Target and Mechanism of Action of Novel Anticancer Agents Curaxins | August 11, 2011 | BioSpace - Breaking News |
| Science Translational Medicine Publishes Breakthrough Finding From Cleveland BioLabs and Incuron on Identification of Target and Mechanism of Action of Novel Anticancer Agents Curaxins | August 10, 2011 | Marketwire - Pharma and Biotech |
| Cleveland BioLabs to Present at 2011 Wedbush Life Sciences Management Access Conference | August 09, 2011 | Marketwire - Pharma and Biotech |
| Cleveland BioLabs to Host Quarterly Update Call on August 15 | August 08, 2011 | Marketwire - Pharma and Biotech |
| Cleveland BioLabs gets $1.5M increase from DOD | June 30, 2011 | Health News - CNBC |
| Department of Defense Increases Development Contract With Cleveland BioLabs for CBLB502 | June 30, 2011 | Marketwire - Pharma and Biotech |
| Feds add to Cleveland BioLabs contract | June 30, 2011 | Health News - BizJournals.com |
| Mintz Levin Represents Cleveland BioLabs in $23.5 Million Registered Direct Shelf Offering | June 30, 2011 | Biotechnology - Moreover |
| Cleveland BioLabs Added to Russell 3000(R) Index | June 27, 2011 | Marketwire - Pharma and Biotech |
| Cleveland BioLabs Closes $23.5 Million Registered Direct Offering | June 23, 2011 | Marketwire - Pharma and Biotech |
| Cleveland BioLabs raises $22M | June 23, 2011 | Health News - BizJournals.com |
| Cleveland Biolabs Falls 4.96% on Heavy Volume: Watch For Potential Rebound (CBLI) | June 22, 2011 | Biotechnology - Moreover |
| Cleveland BioLabs plans stock sale | June 17, 2011 | Health News - BizJournals.com |
| Cleveland BioLabs to Raise $23.5 Million in Registered Direct Offering | June 17, 2011 | Marketwire - Pharma and Biotech |
| Cleveland BioLabs shares fall on funding concerns | May 31, 2011 | Health News - CNBC |
| Cleveland BioLabs Provides Update on CBLB502 and BARDA Development Contract | May 31, 2011 | Marketwire - Pharma and Biotech |
| Cleveland BioLabs Receives Notice of Patent Allowance From Japan for CBLB502 | May 23, 2011 | Marketwire - Pharma and Biotech |
| Cleveland BioLabs Announces New US Patent Allowances for CBLB502 and CBLB612 | May 16, 2011 | Marketwire - Pharma and Biotech |
| Relatively Low Forward Earnings Yield Detected in Shares of Cleveland Biolabs in the Biotechnology Industry (CBLI, GHDX, CPHD, RGEN, ENZN) | May 16, 2011 | Biotechnology - Moreover |
| Cleveland BioLabs Nominates Former President of Roswell Park Cancer Institute to Board of Directors | May 03, 2011 | Marketwire - Pharma and Biotech |
| Cleveland BioLabs radiation drug ready for potential Japan use | March 18, 2011 | FierceBiotech |
| Video: Joe Salvani Discusses Significance of Cleveland BioLabs Radiation Antidote to Nuclear Crisis in Fukushima, Japan | March 17, 2011 | Marketwire - Pharma and Biotech |
| Cleveland Biolabs Inc. (CBLI) to Present at 13th Annual Biotechnology Industry Organization (BIO) CEO and Investor Conference | February 07, 2011 | Biotechnology - Moreover |
| Cleveland BioLabs to Present at 13th Annual BIO CEO and Investor Conference | February 07, 2011 | Marketwire - Pharma and Biotech |
| Cleveland BioLabs Receives $1.6 Million Development Contract From Defense Threat Reduction Agency of Department of Defense for CBLB502 | January 25, 2011 | Marketwire - Pharma and Biotech |
| Options Brief: Cleveland BioLabs (CBLI) | January 21, 2011 | Biotechnology - Moreover |
| Cleveland Biolabs Inc. Announces Potential Direct Anticancer Effect of CBLB502 | January 20, 2011 | BioSpace - Breaking News |
| Cleveland BioLabs Announces Potential Direct Anticancer Effect of CBLB502 | January 20, 2011 | Marketwire - Pharma and Biotech |
| Cleveland Biolabs Inc. to Raise Approximately $8.39 Million in Registered Direct Offering With Single Institutional Investor | December 27, 2010 | BioSpace |
| Cleveland BioLabs to Raise Approximately $8.39 Million in Registered Direct Offering With Single Institutional Investor | December 23, 2010 | Marketwire - Pharma and Biotech |
| Cleveland BioLabs radiation drug gets incentives | November 30, 2010 | Health News - CNBC |
| Cleveland BioLabs and Incuron Receive $489,000 in Qualifying Therapeutic Discovery Project Grants | November 02, 2010 | Marketwire - Pharma and Biotech |
| Cleveland BioLabs Announces Start of Phase IB Trial for Prototype Curaxin CBLC102 in Russia | November 01, 2010 | Marketwire - Pharma and Biotech |
| Cleveland BioLabs Receives Notice of Patent Allowance From China for CBLB502 | October 19, 2010 | Marketwire - Pharma and Biotech |
| Cleveland Biolabs Inc. Files Registration Statement for Series B Class of Warrants | October 13, 2010 | BioSpace - Breaking News |
| Cleveland BioLabs Files Registration Statement for Series B Class of Warrants | October 13, 2010 | Marketwire - Pharma and Biotech |
| Cleveland BioLabs Granted First Patents for Protectan CBLB612 | October 04, 2010 | Marketwire - Pharma and Biotech |
| Cleveland Biolabs Inc. Announces Results of Second Safety Study for CBLB502 | September 29, 2010 | BioSpace - Breaking News |
| Cleveland BioLabs Announces Results of Second Safety Study for CBLB502 | September 29, 2010 | Marketwire - Pharma and Biotech |
| Cleveland Biolabs Inc. (CBLI) to Present at 9th Annual Biotechnology Industry Organization (BIO) Investor Forum | September 27, 2010 | Biotechnology - Moreover |
| Cleveland BioLabs to Present at 9th Annual BIO Investor Forum | September 27, 2010 | Marketwire - Pharma and Biotech |
| Cleveland BioLabs potential $45 million contract | September 17, 2010 | Health News - CNBC |
| Cleveland BioLabs to Discuss Recent Developments on September 20 Conference Call | September 17, 2010 | Marketwire - Pharma and Biotech |
| Department of Defense Awards Cleveland BioLabs Contract for CBLB502 Fully Valued at $45 Million | September 17, 2010 | Marketwire - Pharma and Biotech |
| Cleveland BioLabs to Present at Rodman & Renshaw 12th Annual Healthcare Conference | September 07, 2010 | Marketwire - Pharma and Biotech |
| Biomedical Advanced Research and Development Authority (BARDA) Exercises $4.1 Million Fourth Option on Cleveland BioLabs Contract to Develop Radiation Countermeasure CBLB502 | July 29, 2010 | Marketwire - Pharma and Biotech |
| Cleveland Biolabs Inc.'s CBLB502 for Reducing the Risk of Death Following Total Body Irradiation During or After a Radiation Disaster Granted Fast Track Status From FDA | July 22, 2010 | BioSpace |
| Cleveland BioLabs Publishes New Study on Curaxins Indicating Potential Antiviral Applications | July 20, 2010 | Marketwire - Pharma and Biotech |
| Cleveland BioLabs Appoints Dr. Michael Paterno Director of Clinical Operations | June 28, 2010 | Marketwire - Pharma and Biotech |
| Cleveland BioLabs Chief Scientific Officer to Speak at Prestigious St. Petersburg International Economic Forum | June 17, 2010 | Marketwire - Pharma and Biotech |
| Cleveland BioLabs to Present at Sidoti Microcap Conference | June 15, 2010 | Marketwire - Pharma and Biotech |
| Cleveland BioLabs Management Shares Milestones and Progress Updates at Annual Meeting | June 08, 2010 | Marketwire - Pharma and Biotech |
| Cleveland BioLabs Adds Regulatory Affairs Expertise to Development Team | May 24, 2010 | Marketwire - Pharma and Biotech |
| Cleveland BioLabs to Present at Rodman & Renshaw 6th Annual Global Healthcare Conference | May 11, 2010 | Marketwire - Pharma and Biotech |
| Cleveland BioLabs Concludes Dosing of Second Safety Study for CBLB502 | May 10, 2010 | Marketwire - Pharma and Biotech |
| Biomedical Advanced Research and Development Authority (BARDA) Exercises Options on Cleveland Biolabs Inc. $15.6 Million Contract to Develop Radiation Countermeasure CBLB502 | April 29, 2010 | BioSpace - Breaking News |
| Biomedical Advanced Research and Development Authority (BARDA) Exercises Options on Cleveland BioLabs $15.6 Million Contract to Develop Radiation Countermeasure CBLB502 | April 29, 2010 | Marketwire - Pharma and Biotech |
| Cleveland Biolabs opens new venture | April 26, 2010 | Health News - BizJournals.com |
| Cleveland BioLabs Announces Launch of Incuron Joint Venture to Develop Curaxin Compounds | April 26, 2010 | Marketwire - Pharma and Biotech |
| Cleveland BioLabs to Provide Update on Development Progress and Corporate Strategy on May 4 Conference Call | April 26, 2010 | Marketwire - Pharma and Biotech |
| Webcast Alert: Cleveland BioLabs Investor Update Call | April 25, 2010 | Biotech News - PR Newswire |
| Cleveland BioLabs Chief Scientific Officer Presents at American Association for Cancer Research Meeting | April 21, 2010 | Marketwire - Pharma and Biotech |
| Cleveland BioLabs to Present at Roth Capital Partners 22nd Annual OC Growth Stock Conference | March 09, 2010 | Marketwire - Pharma and Biotech |
| Cleveland BioLabs Announces Annual Meeting | March 04, 2010 | Marketwire - Pharma and Biotech |
| Drug Stocks Inch Higher; Cleveland BioLabs Sinks | February 26, 2010 | Health News - Fox Business |
| Cleveland Biolabs Inc. Raises $5 Million From Institutional Investors Through Private Placement | February 26, 2010 | BioSpace - Breaking News |
| Cleveland BioLabs Raises $5 Million From Institutional Investors Through Private Placement | February 26, 2010 | Marketwire - Pharma and Biotech |
| Cleveland BioLabs Submits Response to Department of Defense Request for Proposal for Radiation Countermeasure | February 24, 2010 | Marketwire - Pharma and Biotech |
| Cleveland BioLabs Selects PharmaVigilant for Complex Phase I/II Oncology Study | February 24, 2010 | Marketwire - Pharma and Biotech |
| Cleveland BioLabs Granted European Patent for Radiation Protection Drug CBLB502 | January 28, 2010 | Marketwire - Pharma and Biotech |
| Cleveland BioLabs to Present at 12th Annual BIO CEO & Investor Conference | January 27, 2010 | Marketwire - Pharma and Biotech |
| Cleveland BioLabs Doses First Volunteers in Second Safety Study for CBLB502 | January 19, 2010 | Marketwire - Pharma and Biotech |
| Cleveland BioLabs to Respond to Department of Defense Request for Proposal for Radiation Countermeasure | January 12, 2010 | Marketwire - Pharma and Biotech |
| Cleveland BioLabs Receives First U.S. Patent for Radiation Protection Drug CBLB502 | January 06, 2010 | Marketwire - Pharma and Biotech |
| Cleveland BioLabs to Present at OneMedForum | January 05, 2010 | Marketwire - Pharma and Biotech |
| Cleveland Biolabs Inc. Establishes Joint Venture to Develop Curaxin Compounds for Cancer Applications; Bioprocess Capital Ventures Will Contribute $18 Million | December 30, 2009 | BioSpace |
| Cleveland Biolabs Inc. Establishes Joint Venture to Develop Curaxin Compounds for Cancer Applications; Will Contribute $18 Million | December 30, 2009 | BioSpace |
| Cleveland BioLabs Establishes Joint Venture to Develop Curaxin Compounds for Cancer Applications | December 30, 2009 | Marketwire - Pharma and Biotech |
| Cleveland BioLabs President and CEO Reports Progress on Clinical and Corporate Developments | December 22, 2009 | Marketwire - Pharma and Biotech |
